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Abstract
Background: Wound healing in horses is fraught with complications. Specifically, wounds on
horse limbs often develop exuberant granulation tissue which behaves clinically like a benign tumor
and resembles the human keloid in that the evolving scar is trapped in the proliferative phase of
repair, leading to fibrosis. Clues gained from the study of over-scarring in horses should eventually
lead to new insights into how to prevent unwanted scar formation in humans. cDNA fragments
corresponding to CTNNB1 (coding for β-catenin) and PECAM1, genes potentially contributing to
the proliferative phase of repair, were previously identified in a mRNA expression study as being
up-regulated in 7 day wound biopsies from horses. The aim of the present study was to clone full-
length equine CTNNB1 and PECAM1 cDNAs and to study the spatio-temporal expression of
mRNAs and corresponding proteins during repair of body and limb wounds in a horse model.
Results: The temporal pattern of the two genes was similar; except for CTNNB1 in limb wounds,
wounding caused up-regulation of mRNA which did not return to baseline by the end of the study.
Relative over-expression of both CTNNB1 and PECAM1 mRNA was noted in body wounds
compared to limb wounds. Immunostaining for both β-catenin and PECAM1 was principally
observed in endothelial cells and fibroblasts and was especially pronounced in wounds having
developed exuberant granulation tissue.
Conclusion: This study is the first to characterize equine cDNA for CTNNB1 and PECAM1 and to
document that these genes are expressed during wound repair in horses. It appears that β-catenin
may be regulated in a post-transcriptional manner while PECAM1 might help thoracic wounds
mount an efficient inflammatory response in contrast to what is observed in limb wounds.
Furthermore, data from this study suggest that β-catenin and PECAM1 might interact to modulate
endothelial cell and fibroblast proliferation during wound repair in the horse.
Published: 31 January 2008
BMC Physiology 2008, 8:1 doi:10.1186/1472-6793-8-1
Received: 18 July 2007
Accepted: 31 January 2008
This article is available from: http://www.biomedcentral.com/1472-6793/8/1
© 2008 Miragliotta et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 12
(page number not for citation purposes)
BMC Physiology 2008, 8:1 http://www.biomedcentral.com/1472-6793/8/1Background
Repair of wounds located on the limbs, but not the body,
of horses is often accompanied by the formation of exu-
berant granulation tissue (EGT) which behaves clinically
like a benign tumor and resembles the human keloid [1,2]
in that the evolving scar is trapped in the proliferative
phase of repair, leading to fibrosis. This condition ulti-
mately generates extensive scarring, detrimental to func-
tion. Indeed, a recent study reported that approximately
7% of injuries leading to the retirement of racehorses are
the result of a wound [3]. Efforts to enhance wound repair
and to prevent unwanted scar formation in both humans
and horses have been disappointing, possibly owing to
insufficient knowledge of the underlying mechanisms.
We recently identified genes expressed in wound margin
biopsies of horses, using suppression subtractive hybridi-
zation (SSH) [4]. Two hundred and twenty six cDNAs
were found to be differentially expressed during the pro-
liferative phase of repair of normal body wounds, 129 of
which matched against GenBank databases. In the study
described herein, we targeted a previously identified SSH-
derived cDNA fragment corresponding to β-catenin
(CTNNB1) and a second corresponding to equine platelet
endothelial adhesion molecule-1 (PECAM1) for their
potential contribution to the proliferative phase of repair,
which is aberrant following wounding on the limbs of
horses. CTNNB1 had already been demonstrated to play a
role in fibroproliferative disorders [5,6] and PECAM1 was
chosen because of its known interaction with β-catenin
[7].
Beta-catenin is an 88-kDa highly conserved protein that is
a structural component of the adherens junction (AJ), a
cadherin-dependent adhesive structure intricately linked
to the actin microfilament network and located between
adjacent epithelial cells. Beta-catenin is a central mediator
in the canonical wingless (Wnt) signaling pathway, which
exerts remarkable control over cellular phenotype and
behavior [8]. When the Wnt pathway is quiescent, β-cat-
enin participates in AJs which must disassemble to allow
for cell migration, a process critical to epithelialization
following wounding. When freed from intercellular con-
tacts, β-catenin is phosphorylated and targeted for degra-
dation [6]. Activation of the Wnt pathway inhibits
phosphorylation, leading to cytosolic stabilization of β-
catenin. This stabilized form subsequently translocates to
the nucleus where it functions as a transcriptional co-acti-
vator of T cell factor/lymphoid enhancer factor (Tcf/Lef)
target genes [9].
Beta-catenin plays a cell-specific role during wound
repair. Protein levels are transiently elevated in mesenchy-
mal cells during the proliferative phase of repair [5],
which is thought to regulate the growth of dermal fibrob-
lasts [10,11]. Moreover, β-catenin stimulates the growth
of microvascular endothelial cells [12]. In contrast, β-cat-
enin inhibits migration of human epithelial cells in vitro,
which may impair wound closure in vivo [13]. Hyperplas-
tic wounds in man exhibit a prolonged phase of elevated
β-catenin protein levels and concurrent tcf-dependent
transcriptional activation of target genes involved in fibro-
proliferative processes, such as alpha smooth muscle actin
(α-SMA), fibronectin (FN) and collagen type III (COLIII)
[5]. A transgenic mouse model, in which stabilized β-cat-
enin is expressed in mesenchymal cells, develops aggres-
sive fibromatosis (desmoid tumors) and hyperplastic
cutaneous wounds [11].
PECAM1 (CD31) is a 130-kDa transmembrane glycopro-
tein member of the immunoglobulin superfamily that is
constitutively expressed on platelets, specific cells of the
immune system, as well as on endothelial cells, particu-
larly at intercellular junctions [14]. Its ectodomain medi-
ates adhesion [15] while its cytoplasmic portion serves as
a scaffold for cytoskeletal proteins [16] and for signaling
[17]. PECAM1 has been implicated in a number of impor-
tant biological processes including modulation of adhe-
sion [18], cell migration [19], inflammatory cell
infiltration [20,21], phagocytosis by macrophages [22],
endothelial permeability [23] and angiogenesis [24,25].
PECAM1 binds tyrosine-phosphorylated β-catenin having
left AJs and become localized to the cytosol [16]. Pre-
cisely, PECAM1 functions as a reservoir for tyrosine-phos-
phorylated β-catenin, maintaining localization at the
plasma membrane. This dynamic interaction is involved
in the proliferation phase of angiogenesis [16]. Biswas et
al. [7] identified PECAM1 as a modulator of microvascu-
lar endothelial cell proliferation via its participation in the
Wnt signaling pathway, thereby stabilizing and promot-
ing the accumulation of transcriptionally active β-catenin.
In the present study we hypothesized that the temporal
expression pattern of these two genes with potential roles
in angiogenesis and cell proliferation would differ
between body wounds which heal normally and limb
wounds which are predisposed to the formation of EGT in
horses. The specific objectives of this study were to charac-
terize the full-length equine CTNNB1 and PECAM1
cDNAs, and to study the spatio-temporal expression pro-
file of their mRNAs and proteins during the repair of body
and limb wounds. The ultimate objective of our research
program is to contribute to a better understanding of the
dermal repair process, and permit the development of
novel diagnostic and therapeutic strategies to resolve
wound healing complications in the horse and which
could ultimately be extrapolated to man.Page 2 of 12
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Cloning and characterization of equine cDNA for 
CTNNB1 and PECAM1
The cDNA fragments used for the virtual Northern analy-
ses came from sequences previously obtained from a gene
expression profiling experiment using SSH screening
aimed at identifying mRNAs that were increased or
induced during the proliferative phase of wound repair in
the horse [4].
Screening of the size-selected library from equine thoracic
wound margin biopsies collected 7d post-operatively for
CTNNB1 cDNA resulted in the cloning of a truncated
cDNA fragment. Thus, a PCR reaction was performed to
characterize 5' upstream sequences of the ORF. The
equine CTNNB1 cDNA characterized consisted of 2382
bp [GenBank:DQ267491] that included a partial 5'-
untranslated region (UTR) of 9 bp, an ORF of 2346 bp
encoding a 781-amino acid protein with a theoretical
molecular weight of 85.5-kDa, an isoelectric point of 5.5,
and a partial 3'-UTR of 27 bp. Amino acid homology
search in GenBank by PsiBlast revealed orthologous pro-
teins with an overall identity level of 100% for porcine
[GenBank:NM_214367], and 99% to human [Gen-
Bank:NM_001904] and canine [GenBank:XM_856013]
CTNNB1 proteins. The analysis against a protein con-
served domains database (PROSITE) showed the presence
of 9 Armadillo/plakoglobin ARM repeat profiles (R151-
S191, Q193-G236, G235-G277, G277-G319, G319-G362, G400-
G442, G442-A484, Y489-A532, N594-A636).
The virtual Northern analyses allowed determination of
the approximate molecular weight of the full-length
PECAM1 cDNA, which corresponded to 3.1–3.7 kb. The
SSH cDNA fragment was thus used as probe to screen, by
hybridization, the appropriate size-selected cDNA library
generated from equine thoracic wound margin biopsies
collected 7d post-operatively. The full-length equine
PECAM1 cDNA was cloned and consisted of 3381 bp
[GenBank:DQ310372] that included a 5'-untranslated
region (UTR) of 156 bp, an ORF of 2217 bp encoding a
738-amino acid protein with a theoretical molecular
weight of 82.3-kDa, an isoelectric point of 8.2, and a 3'-
UTR of 1008 bp containing one polyadenylation signal.
Amino acid homology search in GenBank by PsiBlast
revealed orthologous proteins with an overall identity
level of 76% to canine [GenBank:XM_848326], 75% to
porcine [GenBank:NM_213907], and 72% to human
[GenBank:NM_000442] and bovine [Gen-
Bank:NM_174571] proteins. The equine sequence deter-
mined herein contains the 16 exons present in the
predominant form of full-length human PECAM1 [26].
While our study does not exclude the possibility of
PECAM1 isoforms in the horse, in normal skin and
wound edge biopsies we detected only the full-length iso-
form for PECAM1.
Temporal expression of CTNNB1 and PECAM1 mRNAs 
in body and limb wounds
Semi-quantitative RT-PCR showed an induction of
CTNNB1 mRNA expression in response to wounding
though up-regulation was less acute than for PECAM1.
The repeated measures linear model revealed a non-signif-
icant effect of site, across time (P = 0.49) when used to
analyze the temporal expression of CTNNB1 mRNA dur-
ing wound repair in the horse, though constitutive expres-
sion of CTNNB1 in unwounded skin at time 0 was
significantly greater in the limb than in the thorax (P =
0.0014; Fig 1). Statistical analysis of the results obtained
for CTNNB1 mRNA expression revealed a significant
effect of time across groups (P = 0.0002). Expression was
induced in thoracic skin in response to wounding, with
significantly elevated levels attained from one week on.
The level of expression of CTNNB1 mRNA was signifi-
cantly greater in thoracic than limb wounds from three
Regulation of equine CTNNB1 mRNA by wounding of thorax and limb skinFig re 1
Regulation of equine CTNNB1 mRNA by wounding of thorax 
and limb skin. Total RNA was extracted from wound margin 
biopsies isolated 1, 2, 3, 4 and 6 weeks post-wounding, then 
used in mRNA expression analyses by semi-quantitative RT-
PCR as described in Methodology. Bar graphs represent the 
average of measures, performed in triplicate, on the mRNA 
of the four horses included in the study. Top: Regulation of 
CTNNB1 mRNA (AF 752 bp) in wound biopsies from the 
thorax and the limb. Bottom: Relative changes in CTNNB1 
mRNA in biopsies of thorax and limb wounds. The intensity 
of CTNNB1 signals was normalized with the control gene 
GAPDH. Different letters denote samples that differed signifi-
cantly (P < 0.05) from time 0 of the same site (a); between 
anatomic sites at the same time (B). Data are presented as 
means ± SEM.Page 3 of 12
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sistent induction of CTTNB1 in thoracic wounds.
The repeated measures linear model revealed a non-signif-
icant effect of site, across time (P = 0.93), when used to
analyze the temporal expression of PECAM1 mRNA dur-
ing wound repair in the horse, though constitutive expres-
sion of PECAM1 in unwounded skin was significantly
greater in the limb than in the thorax (P < 0.03; Fig 2).
Thereafter the effect of site varied from one time to
another. Semi-quantitative RT-PCR showed an induction
of mRNA expression in response to wounding, with a sig-
nificantly higher level reached in thoracic than in limb
wounds after only one week of repair (P = 0.0174).
PECAM1 mRNA expression did not return to baseline lev-
els by the end of the 6-week study at either location.
Indeed, the effect of time, across sites, was significant (P <
0.0001).
Protein localization in healing body and limb wounds
Immunoblotting showed a specific band of the expected
molecular weight in equine skin protein extract for β-cat-
enin determining that the commercial mouse mono-
clonal antibody raised against amino acids 680–781
mapping at the C-terminus of β-catenin of human origin
(sc-7963; Santa Cruz Biotechnology) was specific for
equine tissues (data not shown). Cellular localization of
β-catenin in normal skin and wound tissues was deter-
mined by immunohistochemistry. In normal unwounded
skin, the epidermis showed nuclear reactivity, which was
also present in the sheaths of the hair follicles and some
sebaceous glands (Fig 3a). No immunoreactive signal was
noted in the extracellular matrix (ECM) or the fibroblasts
populating the dermis, but endothelial cells were posi-
tively stained on their luminal side (Fig 3b). No qualita-
tive or quantitative differences in staining were detected
between thoracic and limb skin samples, nor later on
between thoracic and limb wound samples. While epithe-
lialization was incomplete two weeks following wound-
ing, the intact epidermis adjacent to the wound continued
to show nuclear reactivity but also new membrane reactiv-
ity at the wound edge (Fig 3c). The dermis contiguous to
the wound showed the same pattern as pre-operatively
while the granulation tissue filling the wound bed showed
nuclear and cytoplasmic staining of both the fibroblasts
and the microvascular endothelial cells. In the fourth
week of repair the epidermis and the dermis showed the
same staining pattern as described for the second week
samples. The granulation tissue fibroblasts were strongly
stained in a nuclear fashion while the endothelial cells
were also labelled with the anti-β-catenin antibody. Six
weeks following wounding, immunostaining for β-cat-
enin protein had started to wane. The epidermis, which
covered the wound bed in most cases, showed the nuclear
staining pattern observed pre-operatively in intact skin.
The granulation tissue, which had become less cellular,
was weakly stained compared to that of four week biop-
sies and exhibited a staining pattern more nuclear than
cytoplasmic. In three month and six month old EGT,
fibroblasts as well as endothelial cells appeared strongly
stained in a nuclear/cytoplasmic fashion (Fig 3d).
The commercially available PECAM1 antibody (sc-1506;
Santa Cruz Biotechnology) stained very specifically
endothelial cell membranes, as expected. The PECAM1
antibody stained the luminal membrane of endothelial
cells lining dermal blood vessels in normal, unwounded
skin (Fig 4a) and in wound biopsies. Consequently, the
staining pattern paralleled that of angiogenesis following
wounding. At weeks 1 and 4 the presence of more blood
vessels within the granulation tissue filling the wound bed
translated into more PECAM1 immunostaining, particu-
larly in limb wounds (Figs 4c and 4d). In 3 month old
EGT, there were large and strongly PECAM1-positive ves-
Regulation of equine PECAM1 mRNA by wounding of thorax and limb skinFig re 2
Regulation of equine PECAM1 mRNA by wounding of thorax 
and limb skin. Total RNA was extracted from wound margin 
biopsies isolated 1, 2, 3, 4 and 6 weeks post-wounding, then 
used in mRNA expression analyses by semi-quantitative RT-
PCR as described in Methodology. Bar graphs represent the 
average of measures, performed in triplicate, on the mRNA 
of the four horses included in the study. Top: Regulation of 
PECAM1 mRNA [amplified fragment (AF) 548 bp] in wound 
biopsies from the thorax and the limb. Bottom: Relative 
changes in PECAM1 mRNA in biopsies of thorax and limb 
wounds. The intensity of PECAM1 signals was normalized 
with the control gene GAPDH. Different letters denote sam-
ples that differed significantly (P < 0.05) from time 0 of the 
same site (a); between anatomic sites at the same time (B). 
Data are presented as means ± SEM.Page 4 of 12
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and more organized such that the PECAM1 staining was
slightly weaker (Fig 4b).
Discussion
The purpose of this study was to determine the temporal
expression of CTNNB1/β-catenin and of PECAM1 during
the repair of body and limb wounds in horses in an effort
to define some of the molecular mechanisms leading to
undue scarring. At the time of the study, the cDNAs were
not characterized for the horse therefore both were cloned
and sequenced. Hybridization of the size-selected librar-
ies revealed the clones containing the full-length sequence
of PECAM1 but only a truncated fragment of CTNNB1.
Fortunately, the latter allowed the design of a homolo-
gous oligonucleotide that was used, along with a heterol-
ogous one, to amplify the full-length equine CTNNB1
cDNA sequence.
Results show equine CTNNB1 to be a highly conserved
gene and to contain all 16 exons reported in humans. The
excellent identity of the sequences for CTNNB1 in mam-
mals (close to 100%) validates the quality of the equine
sequence we obtained despite the required amplification
by PCR. A high rate of degradation may have contributed
to our inefficiency in obtaining the correct hybridization
size for the full-length CTNNB1 gene in horse; indeed, in
man there exists in the 3'-UTR one copy of AU-rich ele-
Immunohistochemical localization of β-catenin in the epidermal compartment of equine skin or woundsFigure 3
Immunohistochemical localization of β-catenin in the epidermal compartment of equine skin or wounds. Immunohistochemis-
try was performed on formalin-fixed, paraffin embedded tissues incubated with anti-β-catenin antibody as described in Method-
ology. Staining was absent when the primary antibody was omitted or substituted with normal serum (data not shown). The 
scale bar is equal to 0.1 mm. a) Unwounded limb skin. H = hair follicle. b) Unwounded limb skin. Endothelial cells stained with 
β-catenin antibody. c) Wound margin biopsy taken from 2 week old limb wound. WM = wound margin. d) 3 month old exu-
berant granulation tissue.Page 5 of 12
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mRNAs.
CTNNB1, first cloned by McCrea et al. [27] in Xenopus
laevis, shows no similarity in sequence to the genes for the
α-catenins reported in other species while the β-catenin
protein shares 70% amino acid identity with both pla-
koglobin, found in desmosomes, and the product of the
Drosophila segment polarity gene "armadillo". Analysis
of equine predicted β-catenin, against a protein conserved
domains database (PROSITE), showed the presence of 9
Armadillo/plakoglobin repeat profiles, an approximately
40 amino acid long repeated sequence motif. Proteins
that contain this type of domain combine structural roles
and signaling functions, by generating and transducing
signals affecting gene expression [28]. The calculated
expected molecular weight (85,5 kDa) concords with that
previously reported for other species.
A preliminary mRNA gene expression profiling study
identified a cDNA fragment that corresponded to
PECAM1, suggesting its up-regulation in response to der-
mal wounding [4]. The equine sequence determined
herein contained the 16 exons present in the full-length
human PECAM1, the predominant isoform detected in
human tissue and endothelial cells [26]. This contrasts
with the main isoform found in murine endothelium
which lacks exons 14 and 15 [29]. While it is possible that
Immunohistochemical localization of PECAM1 in the dermal compartment of equine skin or wounds tissuesFigure 4
Immunohistochemical localization of PECAM1 in the dermal compartment of equine skin or wounds tissues. Immunohisto-
chemistry was performed on formalin-fixed, paraffin embedded tissues incubated with anti-PECAM1 antibody as described in 
Methodology. The blood vessel endothelial cells are stained. Staining was absent when the primary antibody was omitted or 
substituted with normal rabbit serum (data not shown). The scale bar is equal to 0.2 mm. a) Unwounded thoracic skin. b) 6 
month old exuberant granulation tissue. c) Wound margin biopsy (focusing on granulation tissue) taken from 4 week old heal-
ing thoracic wound. d) Wound margin biopsy (focusing on granulation tissue) taken from 4 week old healing limb wound.Page 6 of 12
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at least in skin, the full-length form predominates.
Processes occurring during the proliferative phase of
wound repair ensure restoration of the structural and
functional characteristics of skin which depend on both
the epithelial and the mesenchymal components of the
wound. The severity of scarring of horse limb wounds is
related to an excessive proliferative phase where angiogen-
esis and fibroplasia are exacerbated [30-33]. This may
result from dysregulation of the molecular components
governing the growth of mesenchymal cells. In the study
reported herein we have focused on two molecules,
CTNNB1 and PECAM1, for their proposed role in
endothelial cell and fibroblast proliferation.
The temporal patterns we report for mRNA expression of
CTNNB1 and PECAM1 resemble one another. Both genes
were constitutively expressed in normal intact skin, but
while dermal trauma induced the expression of both
mRNAs, the response was more acute for PECAM1 whose
levels were significantly increased over baseline one week
following wounding compared to two weeks for
CTNNB1. This significant up-regulation of mRNA was
maintained for the duration of the study for PECAM1 at
both anatomic locations and for CTNNB1 in thoracic
wounds; conversely, expression of CTNNB1 in limb
wounds was not significantly elevated following wound-
ing. Finally, mRNA expression in thoracic wounds signifi-
cantly surpassed that of limb wounds for PECAM1, one
week post-wounding, and for CTNNB1, three, four and six
weeks post-wounding.
While possible that the temporal pattern of mRNA expres-
sion might reflect the different levels at the various sam-
pling sites, the wounds were very close together such that
we think it unlikely that anatomic or metabolic differ-
ences (blood supply, muscle coverage, etc) are important.
Previous studies using a similar model [30-33] have not
reported an influence of the exact location on the body or
the lower limb. Likewise a current study has shown no dif-
ference in the rate of closure between wounds located dis-
tally or more proximally on the lower limb (Monteiro et
al, unpublished data).
The correspondence in the patterns of mRNA expression
following wounding is consistent with the PECAM1/β-
catenin protein partnership proposed by Biswas et al.
[7,34,35]. Indeed, the cytoplasmic portion of PECAM1
binds cytosolic β-catenin and this dynamic interaction is
involved in angiogenesis [16]. More specifically, by
enhancing the accumulation of stabilized β-catenin,
PECAM1 modulates microvascular endothelial cell prolif-
eration via transcriptional activation of growth promoting
genes. Furthermore, a significant increase in PECAM1
mRNA levels preceded that of CTNNB1 following wound-
ing in our study, consistent with the fact that upon
cytokine stimulation endothelial cells initially induce
PECAM1, followed by an increased expression of β-cat-
enin [7].
While one might have anticipated higher levels of equine
CTNNB1 mRNA in limb wounds predisposed to the
development of EGT, a form of fibroproliferative disease,
our opposite findings may reflect the mechanism of post-
transcriptional regulation of β-catenin during wound
repair, which controls how mRNA is translated into pro-
tein. Indeed, Cheon et al. documented that in the absence
of any change in mRNA level, β-catenin protein, expressed
primarily in dermal mesenchymal cells, was nonetheless
transiently increased during the proliferative phase of nor-
mal wound healing in humans while exhibiting a sus-
tained elevation in hyperplastic wounds [5]. Thus, a lack
of correlation between mRNA and protein levels might
underlie our unexpected findings; specifically, why
CTNNB1 mRNA levels remained elevated when immu-
nostaining for β-catenin waned, and why CTNNB1 mRNA
levels in thoracic wounds surpassed those of limb wounds
at weeks 3, 4 and 6 of healing.
In the horse, epithelial cells migrate slowly on limb
wounds which are concurrently afflicted by over-abun-
dant fibroblast proliferation; both are influences attrib-
uted to β-catenin protein [10,13]. Although
immunohistochemical studies did not suggest quantita-
tive differences in β-catenin expression between body and
limb wounds, our investigation did reveal that while the
protein remains transcriptionally active (nuclear stain) in
dermal mesenchymal cells for the duration of the study,
the intensity of the stain diminishes between the 4th and
6th weeks of healing. This pattern suggests that the signal
would have disappeared entirely from normally healed
wounds had the study been extended a few weeks. Con-
versely, strong immunostaining for β-catenin was
detected in biopsies of 3 and 6 month old EGT, a condi-
tion characterized by exaggerated angiogenesis and fibro-
plasia and which resembles hyperplastic scarring in man
in which a prolonged duration of β-catenin protein eleva-
tion has been reported [5]. Our findings may indicate that
mesenchymal cells in EGT are behaving as though in a
prolonged active proliferative phase of wound healing. In
other words, the high levels of β-catenin would encourage
proliferation and motility of the dermal cells, generating a
larger dermal component to the wounds and hampering
remodeling which requires reduced β-catenin levels [5].
While the design of our study cannot establish a cause-
and-effect relationship between the prolonged elevation
of β-catenin and the development of equine EGT, trans-
genic mouse models expressing a stabilized form of β-cat-Page 7 of 12
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cutaneous wounds [11]. Fibroblasts derived from these
mice display increased proliferation, motility and inva-
siveness when grafted into nude mice. Moreover, primary
cell cultures demonstrate Tcf-dependent transcriptional
activation [11] consistent with the hypothesis that nuclear
β-catenin transactivation of target genes is a primary com-
ponent of fibrosis.
In contrast to the membrane staining of epithelial cells
reported by Cheon et al [5], we identified nuclear β-cat-
enin within epithelial cells of intact skin. Our finding is
similar to that of Tsuji et al. [36] who report nuclear
immunostaining for β-catenin from the upper spinous to
the granular cells in normal, intact human epidermis. The
presence of stabilized, transcriptionally active β-catenin
no doubt reflects keratinocyte proliferation and differenti-
ation in response to continued renewal of the epithelial
component of equine skin [37,38].
While PECAM1 is best known as a promoter of angiogen-
esis, its ability to facilitate neutrophil transendothelial
migration [20,21] and thus boost the acute inflammatory
response [39] is particularly intriguing in view of the data
obtained herein. Indeed, it is tempting to draw a parallel
between the inefficient and prolonged inflammatory
response to wounding in the horse limb [33] and the sig-
nificantly inferior expression of PECAM1 mRNA in
wounds at this site compared to those of the thorax, one
week following injury. Conversely, while differences in
expression between the two sites disappear from the sec-
ond week on, one might have expected an increase in limb
wounds where new blood vessels are particularly abun-
dant within the granulation tissue [33], in relation to
PECAM1's role in angiogenesis. Interestingly, the expres-
sion pattern of PECAM1 isoforms has been shown to
change during tube formation in vitro, indicating special-
ized roles for specific isoforms of PECAM1 during angio-
genesis [26]. While our data suggest that we have cloned
the predominant isoform of equine PECAM1, it is possi-
ble that another isoform is responsible for modulating
endothelial cell adhesive properties during angiogenesis
in the horse. Finally, the PECAM1 mRNA expression pat-
tern found in our study corroborates previous assertions
concerning the sluggishness hindering the repair of
equine wounds, particularly those located on the extrem-
ities [1,30,33]. To this effect, a recent study in mice
showed that both mRNA and protein expression of
PECAM1 were induced three days following dermal
wounding but mRNA expression returned to baseline by
day 12 [40]. In contrast, expression of equine PECAM1
mRNA was significantly up-regulated in both thoracic and
limb wounds for the 6-week duration of the study.
Immunohistochemistry revealed that, as expected of an
endothelial cell marker, PECAM1 is principally present in
blood vessels. As such, our data reflect that previously
reported by Lepault et al. [33] who documented, histolog-
ically, more pronounced angiogenesis in healing limb
than body wounds of horses. The concomitant presence
of PECAM1 and β-catenin on endothelial cells of wound
granulation tissue further supports the dynamic interac-
tion between these two molecules, which may modulate
the proliferation phase of angiogenesis [7,16].
Conclusion
This study is the first to characterize equine cDNA for
CTNNB1 and PECAM1 and to document that the genes
are expressed over the different phases of wound repair in
horses. Our findings suggest that β-catenin and PECAM1
might interact to modulate endothelial cell and fibroblast
proliferation during wound repair in the horse.
Most previous studies investigating the roles of β-catenin
and PECAM1 in wound healing have used in vitro tech-
niques. Since wound repair is a complex process involving
the interplay of several cell types, signaling pathways,
extracellular matrix components and soluble factors, the
role of various factors and their interactions may best be
evaluated using an in vivo approach. Thus, while data
interpretation can be challenging, the value of our study
lies in the fact that the findings are more representative of
what truly occurs in the patient.
In an effort to develop targeted therapies to prevent the
formation of EGT leading to excessive scarring of equine
limb wounds, future studies should quantitatively verify
the temporal protein expression of β-catenin and
PECAM1 and attempt to elucidate how the two molecules
interact. The clues gained from studying the equine model
may eventually lead to new insights into how to prevent
unwanted scar formation in humans.
Methods
Cloning of equine CTNNB1 and PECAM1
Isolation of the full-length equine cDNAs was undertaken
by screening size-selected cDNA libraries. The sizes of the
full-length equine PECAM1 and CTNNB1 cDNA were esti-
mated by virtual Northern blot analysis. Briefly, total RNA
was isolated from a wound edge biopsy obtained 7 days
following creation of a square 6.25 cm2 full-thickness
wound on the lateral thoracic wall [4] and transformed
into cDNA by the SMART cDNA synthesis method (BD
Biosciences Clontech, Mississauga ON) as described [41].
The cDNA was separated by gel electrophoresis, trans-
ferred onto a nylon membrane and hybridized with an
equine radioactive probe (CTNNB1 = 535 bp: [Gen-
Bank:DN625863]; PECAM1 = 492 bp: [Gen-
Bank:DN625893]) generated from a previous genePage 8 of 12
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hybridized size, a specific library was established via the
pDrive plasmid cloning technique (Qiagen PCR cloning
kit; Qiagen, Mississauga ON) and screened by radioactive
hybridization as described [41]. Positive hybridizing bac-
terial colonies were grown, their plasmid contents were
isolated (QIA-prep, Qiagen) and the size of the cloned
cDNA was analyzed via gel electrophoresis analysis fol-
lowing EcoR1 digestion.
Since only a 3'-truncated cDNA fragment was obtained for
CTNNB1 following library screening, a PCR reaction was
performed to characterize 5' upstream sequences. Oligos
were designed based on conserved regions of human
[GenBank:NM_001904], swine [GenBank:NM_214367]
and murine [GenBank:NM_007614] sequences. PCR reac-
tions were performed using SMART cDNAs from a 7 day
wound edge biopsy, Advantage 2 DNA polymerase (BD
Biosciences Clontech) and PCR primers (sense: 5'-GCGT-
GGACAATGGCTACYCAAGC-3'; anti-sense: 5'-CCAG-
GCCAGCTGATTACTGTCAC-3'). The PCR product was
cloned in the pDrive plasmid and produced as described
above.
The cDNAs were sequenced via the dideoxy sequencing
method (Big Dye Terminator 3.0; ABI Prism, Applied Bio-
System, Branchburg NJ) and analyzed on an ABI Prism
310 sequencer (Applied BioSystem). Nucleic acid
sequences were analyzed by BLAST and protein sequences
deduced from cDNAs were analyzed by PSI- and PHI-
BLAST [42] against GenBank data banks.
Equine tissues and RNA extraction
Thoracic and limb normal skin as well as wound edge
biopsies were taken at specific times during the repair
process from four normal, 2-to-3 year old Standardbred
mares, as described [33]. Briefly, five square 6.25 cm2
areas were excised on the dorso-lateral aspect of one ran-
domly assigned metacarpus beginning just above the fet-
lock, and on the lateral thoracic wall, 1.5 cm apart in a
staggered vertical column, then left to heal by second
intention. Excised skin from the lowermost wound was
kept as a time 0 sample. One wound per site (thorax;
limb) was sampled at the following times in each horse:
1, 2, 3, 4, and 6 weeks. To avoid repeated trauma, each
wound, beginning with the most distal one, was desig-
nated for a single biopsy. Full-thickness specimens were
taken with an 8 mm diameter biopsy punch to include a
3-to-4 mm strip of peripheral skin, the migrating epithe-
lium and a 3-to-4 mm strip of granulation tissue from the
wound center, when present. Biopsy samples were divided
in half; one half was formalin-fixed and paraffin-embed-
ded (FFPE) for immunohistochemical studies while the
other was snap-frozen in liquid nitrogen and stored at -
80°C until further processing. Total RNA from all samples
was extracted and analyzed as previously described [43].
Samples of 3 and 6 month old EGT were obtained from
two clinical cases presented to the Centre Hospitalier Uni-
versitaire Vétérinaire of the Université de Montréal and
FFPE for immunohistochemistry. These experiments were
approved by the Animal Ethics Committee of the Faculté
de Médecine Vétérinaire of the Université de Montréal
and were sanctioned by the Canadian Council on Animal
Care.
Semi-quantitative RT-PCR analyses of temporal 
expression of mRNA
Total RNA was first transformed into cDNA. One µg of
total RNA from samples of healing thoracic wounds (n =
4 mares) was pooled for each biopsy time; the same was
done for limb wound samples. From each of these pools,
RNA was reverse-transcribed with an oligo-dT30 primer
and PowerScript (BD Biosciences Clontech) to generate
the first strand cDNA using the SMART PCR cDNA synthe-
sis kit (User manual: PT3041-1; BD Biosciences Clontech)
[44]. Second cDNA strands were produced and PCR-
amplified using Advantage 2 DNA polymerase (BD Bio-
sciences Clontech). To perform semi-quantitative RT-
PCR, SMART cDNA pools were used in a 25 µl PCR reac-
tion with the Advantage 2 DNA polymerase kit (BD Bio-
sciences Clontech). Gene-specific PCR primers were
designed in the open reading frame (ORF) of the equine






dehydrogenase (GAPDH; sense: 5'-CAAGTTCCAT-
GGCACAGTCACGG-3'; anti-sense: 5'-AAAGTGGTCGTT-
GAGGGCAATGC-3'; [GenBank:AF157626]) [4]. For all
samples, PCR was performed in triplicate by Mastercycler®
ep. The number of cycles used was optimized for each
gene to fall within the linear range of PCR amplification:
GAPDH = 18 cycles; CTNNB1 = 23 cycles; PECAM1 = 22
cycles. The PCR reactions (20 µl/reaction) were resolved
on a 2% TAE-agarose gel (40 mM Tris acetate; pH 8; 1 mM
EDTA) with ethidium bromide (0.5 µg/ml); PCR products
were visualized by UV and the images were digitized. The
digitized signals for each gene were analyzed by densit-
ometry using the NIH Image program [45].
Immunoblot analyses
Specimens of equine skin and platelets were homoge-
nized in M-PER buffer (Pierce, Rockford, IL) that was sup-
plemented with a mix of protease inhibitors (Complete;
Roche Applied Science, Laval, QC) as recommended by
the manufacturer. Samples were homogenized at 7,000
rpm with a polytron PT1300D (Kinematica AG, Littau-
Lucerne, Switzerland). The protein extracts were centri-Page 9 of 12
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supernatant (whole cell extract) was stored at -80°C until
electrophoretic analyses were performed. Protein concen-
tration was determined by the Bradford method [46] (Bio-
Rad Protein assay, Bio-Rad Laboratories Inc., Hercules,
CA). Protein extracts (100 µg proteins/sample) were heat-
treated (5 min, 100°C) and size-fractionated via a one-
dimensional SDS-PAGE, then electrophoretically trans-
ferred onto polyvinylidene difluoride membranes (PVDF;
Hybond-P, Amersham Pharmacia Biotech). Immunoblots
were performed as described [47]. Membranes were incu-
bated either with the mouse anti-human β-catenin mono-
clonal antibody (dilution 1:1,000; sc-7963; Santa Cruz
Biotechnology, Inc.) or with the goat anti-mouse PECAM-
1 polyclonal antibody (dilution 1:200; sc-1506; Santa
Cruz Biotechnology, Inc. Santa Cruz, CA). As secondary
antibodies a sheep anti-mouse IgG-HRP (dilution
1:10,000; NA931; Amersham Pharmacia Biotech) and a
donkey anti-goat IgG-HRP (dilution 1:5,000; sc-2020;
Santa Cruz Biotechnology, Inc.) were used. Detection of
immunoreactive proteins was performed by the enhanced
chemiluminescence system (ECL Plus, Amersham Phar-
macia Biotech) following the manufacturer's protocol,
and exposed to Hyperfilm (Amersham Pharmacia Bio-
tech). Autoradiographic images were digitized using a
ScanMaker 9800XL flatbed scanner (Microtek lab, Inc.,
Redondo Beach CA).
Immunohistochemical localization of β-catenin and 
PECAM1
PBS-buffered formalin-fixed tissues from both locations
(thorax and limb) in all four horses were prepared as
described [47]. Paraffin-embedded tissues were cut to 3
µm thickness, mounted on SuperfrostPlus slides (Fisher
Scientific, Pittsburgh PA), deparaffinized and then rehy-
drated. Antigenicity lost during the fixation process was
retrieved by pressure cooker heat treatment for 15 min
[47]. Non-specific binding sites were saturated by 30 min
incubation in blocking buffer: TBS (100 mM Tris; pH 7.5;
150 mM NaCl), 1% bovine serum albumin and 1% fat-
free skim milk. For the antibody raised in goat, the fat-free
skim milk was omitted; the saturation step was substi-
tuted by 30 min incubation in TBS-tween (100 mM Tris;
pH 7.5; Tween 0.2%) Tissue sections were incubated over-
night at 4°C with the primary antibodies (β-catenin 1:25;
PECAM1 1:50) diluted in blocking buffer. Negative con-
trol tissue sections were incubated similarly. After three 10
min washes in TBS, complexes were detected by incuba-
tion for 2 h at room temperature with an anti-goat/mouse
IgG alkaline phosphatase conjugated (Sigma-Aldrich)
diluted to 1:100 in blocking buffer. Tissue sections were
washed twice in TBS and once in TBS-MgCl2 (100 mM Tris
pH 9.5, 50 mM MgCl2) and incubated with the NBT/BCIP
alkaline phosphatase substrate (Roche Applied Science).
Sections were mounted in Vectamount® Permanent
Mounting Medium (Vector Laboratories, Burlingame CA).
Photographs were taken under bright field illumination
using a Nikon Eclipse E400 microscope equipped with a
digital camera (Nikon Coolpix 4500). Digital images were
processed and assembled by Photoshop software (Adobe
Systems Inc., San Jose CA).
Statistical analysis
Gene-specific signals (CTNNB1; PECAM1) were normal-
ized with corresponding GAPDH signals for each sample.
A repeated-measures (RM) linear model, with site (thorax
vs limb) and biopsy time as within-subject factors, was
used to determine the effects of site and time on gene
expression. When the RM linear model indicated signifi-
cant differences (P < 0.05), a priori contrasts were used to
compare pre-selected individual means. All analyses were
carried out with a P value < 0.05, using SAS v. 9.1. (Cary,
N.C.).
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